WO1992009271A1 - Composition pour des preparations pharmaceutiques solides contenant des vitamines d3 actives et son procede de preparation - Google Patents
Composition pour des preparations pharmaceutiques solides contenant des vitamines d3 actives et son procede de preparation Download PDFInfo
- Publication number
- WO1992009271A1 WO1992009271A1 PCT/US1991/002846 US9102846W WO9209271A1 WO 1992009271 A1 WO1992009271 A1 WO 1992009271A1 US 9102846 W US9102846 W US 9102846W WO 9209271 A1 WO9209271 A1 WO 9209271A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- vitamins
- pharmaceutical preparations
- solid pharmaceutical
- active vitamins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Definitions
- This invention relates to a composition for solid pharmaceutical preparations containing active vitamins D 3 and a process for the preparation thereof, and more particularly to a composition for solid pharmaceutical preparations containing active vitamins D 3 in which hydroxypropyl methyl cellulose is used as an excipient.
- active vitamins D 3 are labile and sensitive to heat and light and apt to be readily oxidized, so that the formation of pharmaceutical preparations containing active vitamins D 3 requires to stabilize them.
- the preparations are obtained by dissolving active vitamins D 3 together with bile acids, cholesterols or polyvinyl pyrrolidone in an alcoholic solvent such as ethanol, methanol, propanol or the like which permits both to be dissolved therein, followed by removal of the solvent under reduced pressure.
- an alcoholic solvent such as ethanol, methanol, propanol or the like which permits both to be dissolved therein.
- each of the proposed methods exhibits a disadvantage of causing the composition to be partially resinified during the removal of the solvent under reduced pressure.
- each of the conventional methods proposed causes the composition to be rendered non-uniform in grain size when it is pulverized.
- composition for solid pharmaceutical preparations of active vitamins D 3 as disclosed in Japanese Patent Application Laid-Open Publication No. 155309/1984.
- the present invention has been made in view of the foregoing disadvantage of the prior art.
- the inventors have made a careful study for the purpose of preparing a composition for solid pharmaceutical preparations which is capable of stabilizing active vitamins D 3 , having a uniform content and facilitating the handling.
- a composition for solid pharmaceutical preparations containing active vitamins D 3 which comprises hydroxypropylmethyl cellulose (hereinafter referred to as
- HPMC HPMC
- an active vitamins D 3 and a polymer which is readily soluble in an organic solvent each attached to HPMC meets such requirements.
- composition for solid pharmaceutical preparations containing active vitamins D 3 which is capable of permitting the active vitamins D 3 to be significantly thermally stabilized and being improved in handling.
- compositions containing active vitamins D 3 which is capable of highly facilitating the preparation while ensuring thermal stability of the vitamins D 3 .
- a composition for solid pharmaceutical preparations containing active vitamins D 3 comprises hydroxypropyl methyl cellulose, and an active vitamin D 3 and a polymer which is readily soluble in an organic solvent each attached to the hydroxypropyl methyl cellulose.
- a process for preparing such a composition as described above uses an alcoholic solvent.
- the polymer which is readily soluble in an organic solvent includes polyvinyl pyrrolidone (hereinafter referred to as "PVP"), HMPC and the like.
- the active vitamins D 3 of the present invention include vitamins D 3 of which positions 1 ⁇ and/or 25 are subject to hydroxidation, such as, for example, 1 ⁇ - hydroxycholecalciferol; 25-hydroxycholecalciferol; 1 ⁇ , 25- dihydroxycholecalciferol; 26, 26, 26, 27, 27, 27-hexafluoro-1 ⁇ , 25-dihydroxycholecalciferol (hereinafter referred to as "ST- 630); 1 ⁇ , 25-dihydroxycholecalciferol; 24, 25- dihydroxycholecalciferol, 1 ⁇ -dihydroxycholecalciferol; 1 ⁇ , 25- dihydroxy-26, 27-dimethylcholecalciferol; 1 ⁇ -hydroxy-26, 27- dimethylcholecalciferol; 25-hydroxy-26, 27- dimethylcholecalciferol; 1 ⁇ , 25-dihydroxy-24, 24-difluoro-26, 27-dimethylcholecalciferol; 1 ⁇ , 25-dihydroxy-26,
- the polymer which is readily soluble in an organic solvent is loaded in an amount of from 0.1% to 50% by weight and preferably from 0.1% to 35% by weight in the composition.
- composition of the present invention is obtained by preparing HPMC using an alcoholic solution in which the active vitamins D 3 and the polymer which is readily soluble in an organic solvent are dissolved.
- the alcoholic solvent suitable for use for this purpose includes, for example, ethanol
- HPMC acts as an excipient. Any prior art is silent concerning the use of HPMC as a sole excipient in wet granulation as in the present
- HPMC highly exhibits a film forming property, therefore, the granulation of a composition using a solvent in which HPMC is dissolved causes removal and subsequent pulverization of the composition to be rendered difficult or troublesome.
- the composition of the present invention is prepared using the alcoholic solvent in which HPMC is dissolved.
- the use of the alcoholic solvent permits the surface of HPMC particles acting as a nucleus of the composition to be dissolved in the solvent, so that the active vitamins D 3 are taken in HPMC, resulting in being substantially stabilized.
- composition thus obtained may be formed into pharmaceutical preparations as it is or, if necessary, while being mixed with at least one of any suitable additives known in the art such as an excipient, a degradative agent, a binder, a lubricant, an anti-oxidant, a coating agent, a coloring agent, a corrigent, a surface active agent and the like.
- suitable additives known in the art such as an excipient, a degradative agent, a binder, a lubricant, an anti-oxidant, a coating agent, a coloring agent, a corrigent, a surface active agent and the like.
- the excipient includes, for example, lactose, starch, crystalline cellulose, calcium hydrogenphosphate, light silica, titanium oxide, magnesium metasilicate aluminate, polyethylene glycol and the like.
- the degradative agent includes, for example,
- carboxymethyl cellulose calcium carboxymethylcellulose, sodium carboxymethylcellulose, croscarmellose sodium.
- the binder includes, for example, hydroxypropyl cellulose, gelatin, gum arabic, ethyl cellulose, polyvinyl
- the lubricant includes, for example, stearic acid, magnesium stearate, calcium stearate, talc, hardened oil, fatty saccharide and the like.
- the anti-oxidant includes, for example, dibutyl hydroxytoluene (BHT), gallic propyl, butylhydroxy anisole (BHA), ⁇ -tocopherol, citric acid and the like.
- BHT dibutyl hydroxytoluene
- BHA butylhydroxy anisole
- ⁇ -tocopherol citric acid and the like.
- the coating agent includes, for example, HPMC,
- diethylaminoacetate aminoalkyl methacrylate copolymer, hydroxypropylmethyl cellulose acetate succinate, methacrylic acid coplymer, cellulose acetate trimellitate (CAT), polyvinyl acetate phthalate, and the like.
- the coloring agent includes, for example, a tar pigment, titanium oxide and the like.
- the corrigent includes, for example, citric acid, adipic acid, ascorbic acid, menthol and the like.
- the surface active agent includes, for example, glycerin monostearate, polysorbates, sodium lauryl sulfate,
- composition for solid pharmaceutical preparations according to the present invention may be prepared according to a conventional wet granulation process.
- the a conventional wet granulation process may be used.
- composition is preferably prepared using an apparatus
- the apparatus includes, for example, a fluidized bed type apparatus, a rolling and flowing type apparatus, a centrifugal flowing type apparatus, a vacuum type apparatus.
- TC-5R 500g of HPMC 2910 (hereinafter referred to as "TC-5R") was subject to stirring granulation using a solution prepared by dissolving 5mg of ST-630, 12.5g of BHT and 125g of PVP-K30 in 187.5g of 90% ethanol and then pulverized after drying, to thereby provide a composition of the present invention.
- the composition was sealedly put in a glass bottle and stored at 40°C to examine the stability.
- a variation in residual rate of ST-630 with time was as indicated in Table 1.
- a composition for reference was prepared by adding 5ml of an ethanol solution containing ST-63 of 100 ⁇ g/ml in
- Table 1 clearly reveals that in the reference, decomposition of ST-630 occurred rapidly, whereas ST-630 in the composition of the present invention was stabilized for a long period of time.
- 500g of TC-5R was subject to stirring granulation using a solution prepared by dissolving 5mg of ST-630, 12.5g of BHT and 125g of TC-5R in 187.5g of 90% ethanol and then pulverized after drying, to thereby provide a composition of the present invention.
- 500g of TC-5R was subject to agitating granulation using a solution prepared by dissolving 5mg of ST- 630, 12.5g of BHT and 125g of PVP-K30 in 500g of ethanol and then pulverized after drying, to thereby provide a composition of the present invention.
- Table 2 clearly indicates that in each of the tablets prepared using the composition of the present invention, ST-630 was kept stabilized for a long period of time.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2332013A JPH04198129A (ja) | 1990-11-28 | 1990-11-28 | 活性型ビタミンd↓3類含有組成物 |
JP2/332013 | 1990-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992009271A1 true WO1992009271A1 (fr) | 1992-06-11 |
Family
ID=18250168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/002846 WO1992009271A1 (fr) | 1990-11-28 | 1991-04-25 | Composition pour des preparations pharmaceutiques solides contenant des vitamines d3 actives et son procede de preparation |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0559645A1 (fr) |
JP (1) | JPH04198129A (fr) |
AU (1) | AU8096591A (fr) |
WO (1) | WO1992009271A1 (fr) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994000128A1 (fr) * | 1992-06-22 | 1994-01-06 | Lunar Corporation | PROVITAMINE D 1α-HYDROXY ADMINISTREE PAR VOIE ORALE |
EP0588539A1 (fr) * | 1992-09-18 | 1994-03-23 | Teva Pharmaceutical Industries, Ltd. | Compositions pharmaceutiques stabilisées contenant des dérivés des vitamines D2 et D3 |
EP0508756B1 (fr) * | 1991-04-09 | 1996-10-23 | Takeda Chemical Industries, Ltd. | Préparation stabilisée de vitamine D |
US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
KR100688618B1 (ko) * | 2001-09-12 | 2007-03-09 | 주식회사 유유 | 비타민 d 경구투여용 서방성 약제 조성물 |
WO2007068287A1 (fr) * | 2005-12-15 | 2007-06-21 | Laboratoria Qualiphar | Préparation vitaminique à libération prolongée |
EP2468265A3 (fr) * | 2010-12-04 | 2013-01-02 | DEEF Pharmaceutical Industries Co. | Préparations homogènes contenant de la vitamine D |
US8703187B2 (en) | 2007-04-25 | 2014-04-22 | Warner Chilcott Company, Llc | Vitamin D content uniformity in pharmaceutical dosage forms |
US10300078B2 (en) | 2013-03-15 | 2019-05-28 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
US10493084B2 (en) | 2014-08-07 | 2019-12-03 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
US10668089B2 (en) | 2006-06-21 | 2020-06-02 | Opko Ireland Global Holdings, Ltd. | Method of treating and preventing secondary hyperparathyroidism |
US11007204B2 (en) | 2006-02-03 | 2021-05-18 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US11154509B2 (en) | 2007-04-25 | 2021-10-26 | Eirgen Pharma Ltd. | Methods for controlled release oral dosage of a vitamin D compound |
US11173168B2 (en) | 2016-03-28 | 2021-11-16 | Eirgen Pharma Ltd. | Methods of treating vitamin D insufficiency in chronic kidney disease |
US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7034595B2 (ja) * | 2016-03-23 | 2022-03-14 | 株式会社ファンケル | ビタミンd3安定化組成物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0116755A1 (fr) * | 1983-02-22 | 1984-08-29 | Teijin Limited | Composition pour préparations pharmaceutiques solides de vitamines D3 actives et procédé pour sa préparation |
EP0215596A2 (fr) * | 1985-09-05 | 1987-03-25 | Teijin Limited | Composition pour l'injection de la vitamine D3 activée |
EP0387808A2 (fr) * | 1989-03-13 | 1990-09-19 | Ss Pharmaceutical Co., Ltd. | Compositions pour la préparation de vitamines D3 actives sous forme de dose et procédé pour la préparation de vitamines D3 stables et actives sous forme de dose en utilisant ces compositions |
EP0413727A1 (fr) * | 1988-04-26 | 1991-02-27 | Ellco Food Ab | Lysat de plaquettes sanguines, procede pour sa preparation et milieu de culture cellulaire contenant un tel lysat. |
-
1990
- 1990-11-28 JP JP2332013A patent/JPH04198129A/ja active Pending
-
1991
- 1991-04-25 AU AU80965/91A patent/AU8096591A/en not_active Abandoned
- 1991-04-25 WO PCT/US1991/002846 patent/WO1992009271A1/fr not_active Application Discontinuation
- 1991-04-25 EP EP91910918A patent/EP0559645A1/fr not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0116755A1 (fr) * | 1983-02-22 | 1984-08-29 | Teijin Limited | Composition pour préparations pharmaceutiques solides de vitamines D3 actives et procédé pour sa préparation |
EP0215596A2 (fr) * | 1985-09-05 | 1987-03-25 | Teijin Limited | Composition pour l'injection de la vitamine D3 activée |
EP0413727A1 (fr) * | 1988-04-26 | 1991-02-27 | Ellco Food Ab | Lysat de plaquettes sanguines, procede pour sa preparation et milieu de culture cellulaire contenant un tel lysat. |
EP0387808A2 (fr) * | 1989-03-13 | 1990-09-19 | Ss Pharmaceutical Co., Ltd. | Compositions pour la préparation de vitamines D3 actives sous forme de dose et procédé pour la préparation de vitamines D3 stables et actives sous forme de dose en utilisant ces compositions |
Non-Patent Citations (1)
Title |
---|
STN International Information Services, Data Base: Chemical Abstracts, Accession Number: 100(12): 91354r; & JP-A-58206533 (TEIJIN LTD) 1 December 1983 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0508756B1 (fr) * | 1991-04-09 | 1996-10-23 | Takeda Chemical Industries, Ltd. | Préparation stabilisée de vitamine D |
US5614513A (en) * | 1992-06-22 | 1997-03-25 | Bone Care International, Inc. | Oral 1α-hydroxyprevitamin D |
US5529991A (en) * | 1992-06-22 | 1996-06-25 | Lunar Corporation | Oral 1α-hydroxyprevitamin D |
US6150346A (en) * | 1992-06-22 | 2000-11-21 | Bone Care International, Inc. | Method and composition for treating or preventing osteoporosis |
US5622941A (en) * | 1992-06-22 | 1997-04-22 | Lunar Corporation | Oral 1 α-hydroxyprevitamin D |
US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
WO1994000128A1 (fr) * | 1992-06-22 | 1994-01-06 | Lunar Corporation | PROVITAMINE D 1α-HYDROXY ADMINISTREE PAR VOIE ORALE |
US6133250A (en) * | 1992-06-22 | 2000-10-17 | Bone Care International, Inc. | Oral 1α-hydroxyprevitamin D in methods for increasing blood level of activated vitamin D |
US6147064A (en) * | 1992-06-22 | 2000-11-14 | Bone Care International, Inc. | Oral 1α-hydroxyprevitamin D in composition and method for treating psoriasis |
AU667742B2 (en) * | 1992-09-18 | 1996-04-04 | Teva Pharmaceutical Industries Ltd. | Stabilized pharmaceutical compositions containing derivatives of vitamins D2 and D3 |
US5565442A (en) * | 1992-09-18 | 1996-10-15 | Teva Pharmaceutical Industries Ltd. | Stabilized pharmaceutical compositions containing derivatives of vitamins D2 and D3 |
EP0588539A1 (fr) * | 1992-09-18 | 1994-03-23 | Teva Pharmaceutical Industries, Ltd. | Compositions pharmaceutiques stabilisées contenant des dérivés des vitamines D2 et D3 |
US5804573A (en) * | 1992-09-18 | 1998-09-08 | Teva Pharmaceutical Industries Ltd. | Stabilized pharmaceutical composition containing derivative of vitamins D2 and D3 |
US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
KR100688618B1 (ko) * | 2001-09-12 | 2007-03-09 | 주식회사 유유 | 비타민 d 경구투여용 서방성 약제 조성물 |
WO2007068287A1 (fr) * | 2005-12-15 | 2007-06-21 | Laboratoria Qualiphar | Préparation vitaminique à libération prolongée |
US11007204B2 (en) | 2006-02-03 | 2021-05-18 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US11911398B2 (en) | 2006-02-03 | 2024-02-27 | Opko Renal, Llc | Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US10668089B2 (en) | 2006-06-21 | 2020-06-02 | Opko Ireland Global Holdings, Ltd. | Method of treating and preventing secondary hyperparathyroidism |
US8703187B2 (en) | 2007-04-25 | 2014-04-22 | Warner Chilcott Company, Llc | Vitamin D content uniformity in pharmaceutical dosage forms |
US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
US11154509B2 (en) | 2007-04-25 | 2021-10-26 | Eirgen Pharma Ltd. | Methods for controlled release oral dosage of a vitamin D compound |
US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
EP2468265A3 (fr) * | 2010-12-04 | 2013-01-02 | DEEF Pharmaceutical Industries Co. | Préparations homogènes contenant de la vitamine D |
EP3332773B1 (fr) | 2013-03-15 | 2020-08-26 | OPKO Ireland Global Holdings, Limited | Formulation de vitamine d à libération modifiée stabilisée et son procédé d'administration |
EP3650016B1 (fr) | 2013-03-15 | 2021-05-05 | EirGen Pharma Ltd. | Formulation de vitamine d à libération modifiée stabilisée et son procédé d'administration |
EP2968172B1 (fr) | 2013-03-15 | 2020-07-22 | EirGen Pharma Ltd. | Formulation de vitamine d à libération modifiée stabilisée et son procédé d'administration |
US11253528B2 (en) | 2013-03-15 | 2022-02-22 | Eirgen Pharma Ltd. | Stabilized modified release Vitamin D formulation and method of administering same |
US10357502B2 (en) | 2013-03-15 | 2019-07-23 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
US10350224B2 (en) | 2013-03-15 | 2019-07-16 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
US10300078B2 (en) | 2013-03-15 | 2019-05-28 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
US11007205B2 (en) | 2014-08-07 | 2021-05-18 | Eirgen Pharma Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
US10493084B2 (en) | 2014-08-07 | 2019-12-03 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
US11738033B2 (en) | 2014-08-07 | 2023-08-29 | Eirgen Pharma Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
US11173168B2 (en) | 2016-03-28 | 2021-11-16 | Eirgen Pharma Ltd. | Methods of treating vitamin D insufficiency in chronic kidney disease |
Also Published As
Publication number | Publication date |
---|---|
AU8096591A (en) | 1992-06-25 |
JPH04198129A (ja) | 1992-07-17 |
EP0559645A1 (fr) | 1993-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1992009271A1 (fr) | Composition pour des preparations pharmaceutiques solides contenant des vitamines d3 actives et son procede de preparation | |
US5328903A (en) | Composition for solid pharmaceutical preparations containing vitamin D3 derivative | |
US4729895A (en) | Composition for solid pharmaceutical preparations of active vitamins D.sub.3 | |
DE69832621T2 (de) | Neue pharmazeutische formulierungen mit kontrollierter freigabe von wirkstoffen | |
RU2095054C1 (ru) | Твердая лекарственная форма для орального введения | |
US5126145A (en) | Controlled release tablet containing water soluble medicament | |
RU2103995C1 (ru) | Микрогранулы омепразола и способ их получения | |
EP1039909B1 (fr) | Procede de preparation et composition d'une preparation orale d'itraconazole | |
EP1267844B2 (fr) | Composition pour vitamine a libération soutenue | |
US5487900A (en) | Stabilized vitamin D preparation | |
US4904699A (en) | Nifedipine concentrate stabilized against the influence of light and a process for its preparation | |
JPH07196513A (ja) | 医薬顆粒 | |
CA2466726C (fr) | Compositions de preparation contenant des composes actifs au plan physiologiques et instables aux acides et leur procede de production | |
JP2000191516A (ja) | 経口固形組成物 | |
AU616562B2 (en) | Controlled release therapeutic system for liquid pharmaceutical formulations | |
US20050163846A1 (en) | Preparation composition containing acid-unstable physiologically active compound, and process for producing same | |
KR0172134B1 (ko) | 고형 제제 | |
JP2914690B2 (ja) | 安定なビタミンd▲下3▼類含有製剤 | |
JPH10298074A (ja) | ビタミン類含有組成物 | |
JPH0640921A (ja) | 活性型ビタミンd3 類組成物 | |
JPH0848632A (ja) | エトポシドを含有する固形組成物および固形製剤 | |
JPH0536413B2 (fr) | ||
JPH03169814A (ja) | ニフェジピン持続性製剤の製造法 | |
MXPA00006574A (en) | Method and composition of an oral preparation of itraconazole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU KP KR LK LU MC MG MW NL NO RO SD SE SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991910918 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991910918 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991910918 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |